Compare Ford Motor Company (F) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Mesoblast Limited — how do they compare? Ford Motor Company trades at $14.24 (market cap $56.50B), while Mesoblast Limited trades at $19.08 (market cap $2.31B). The key difference: Ford Motor Company is far larger — about 24.5× Mesoblast Limited's market cap, and Ford Motor Company pays a 4.23% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| F | MESO | |
|---|---|---|
Market Cap | $56.50B | $2.31B |
Sector | Consumer Cyclical | Technology |
52-Week High | $17.44 | $20.96 |
52-Week Low | $10.82 | $11.35 |
Enterprise Value | $185.53B | $2.32B |
Dividend Yield | 4.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $13.93, up 0.44% on the day, with a neutral technical outlook and mixed fundamental signals. The company reported a net loss of $8.18 billion in 2025 despite revenue growth to $187.27 billion, reflecting margin pressure. Recent news highlights labor agreements, EV initiatives, and a 4%+ dividend yield. Analyst consensus is a $15.00 price target with a Hold-heavy rating distribution.
The stock presents a value opportunity with low P/E and P/S ratios, but significant risks include persistent net losses, high debt levels, and competitive pressures in the EV transition. Upside depends on execution of cost controls and successful new product launches, particularly in electric vehicles.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
